Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022


SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Conference call and webcast details:

Monday, November 14, 2022 @ 8:00am ET
Investor domestic dial-in: (800) 715-9871 
Investor international dial-in: +1 (646) 307-1963
Conference ID: 4840587

Live webcast link:

A replay of the webcast will be available on shortly after the conclusion of the event for 90 days.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit Follow @GracellBio on LinkedIn.

Media contacts
Marvin Tang

Kyle Evans

Investor contacts
Gracie Tong

Stephanie Carrington


Cision View original content to download multimedia:

SOURCE Gracell Biotechnologies Inc.

Company Codes: NASDAQ-NMS:GRCL

Back to news